Patrick Hoffmann
38Patents
10h-index
55Co-inventors
74Inventor score
Filing activity: Feb 6, 2004 → Sep 20, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9150664B2 | Binding molecules for BCMA and CD3 | Chemistry; Metallurgy | 54 | Active |
| US9340621B2 | Binding molecules for BCMA and CD3 | Chemistry; Metallurgy | 51 | Active |
| US10294300B2 | Antibody constructs for DLL3 and CD3 | Chemistry; Metallurgy | 28 | Active |
| US8518403B2 | Expression-enhanced polypeptides | Chemistry; Metallurgy | 24 | Active |
| US9587036B2 | Cross-species-specific PSMAxCD3 bispecific single chain antibody | Chemistry; Metallurgy | 23 | Active |
| US9598500B2 | Binding molecules for BCMA and CD3 | Chemistry; Metallurgy | 17 | Active |
| US10301391B2 | BCMA and CD3 bispecific T cell engaging antibody constructs | Chemistry; Metallurgy | 16 | Active |
| US10519241B2 | Antibody constructs for EGFRVIII and CD3 | Chemistry; Metallurgy | 14 | Active |
| US9688760B2 | Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains | Chemistry; Metallurgy | 13 | Active |
| US9765157B2 | Antibody constructs for CDH19 and CD3 | Chemistry; Metallurgy | 10 | Active |
| US10781264B2 | PSMA and CD3 bispecific T cell engaging antibody constructs | Chemistry; Metallurgy | 8 | Active |
| US10059766B2 | Antibody constructs for CDH19 and CD3 | Chemistry; Metallurgy | 7 | Active |
| US10752694B2 | Binding molecules for BCMA and CD3 | Chemistry; Metallurgy | 5 | Active |
| US10683351B2 | Antibody constructs for DLL3 and CD3 | Chemistry; Metallurgy | 4 | Active |
| US10766969B2 | Binding molecules for BCMA and CD3 | Chemistry; Metallurgy | 4 | Active |
| US11434302B2 | Bispecific T cell engaging antibody constructs | Chemistry; Metallurgy | 4 | Active |
| US11084876B2 | Anti-leukocyte adhesion for the mitigation of potential adverse events caused by CD3-specific binding domains | Physics | 3 | Active |
| US9486475B2 | PPS for the prevention of potential adverse effects caused by CD3 specific binding domains | Human Necessities | 3 | Active |
| US11591396B2 | Antibody constructs for DLL3 and CD3 | Chemistry; Metallurgy | 3 | Active |
| US11447567B2 | Antibody constructs for FLT3 and CD3 | Chemistry; Metallurgy | 2 | Active |
| US11472886B2 | Cross-species-specific PSMAxCD3 bispecific single chain antibody | Chemistry; Metallurgy | 2 | Active |
| US10851170B2 | Antibody constructs for CD70 and CD3 | Chemistry; Metallurgy | 2 | Active |
| US11352433B2 | BCMA and CD3 bispecific T cell engaging antibody constructs | Chemistry; Metallurgy | 1 | Active |
| US11661462B2 | Optimized cross-species specific bispecific single chain antibody contructs | Chemistry; Metallurgy | 1 | Active |
| US11155629B2 | Method for treating glioblastoma or glioma with antibody constructs for EGFRVIII and CD3 | Chemistry; Metallurgy | 1 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.